Back to top

pharmaceuticals: Archive

Zacks Equity Research

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

RHHBYNegative Net Change BAYRYPositive Net Change SRPTNegative Net Change VRNAPositive Net Change

Zacks Equity Research

VTRS Down on Late-Stage Study Failure of Eye Disease Drug

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

JNJPositive Net Change BAYRYPositive Net Change VTRSPositive Net Change

Kinjel Shah

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.

JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change KVUEPositive Net Change

Kinjel Shah

J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

AZNNo Net Change JNJPositive Net Change PFENegative Net Change MRKNegative Net Change

Zacks Equity Research

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.

SNYNegative Net Change GILDPositive Net Change KYMRNegative Net Change

Zacks Equity Research

Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change

Ahan Chakraborty

Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?

Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.

NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change

Zacks Equity Research

AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

AZNNo Net Change PRTAPositive Net Change AGENNegative Net Change AKRONegative Net Change

Zacks Equity Research

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

BAYRYPositive Net Change AGENNegative Net Change MDGLNegative Net Change VRNAPositive Net Change

Ahan Chakraborty

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change RXRXPositive Net Change

Sweta Killa

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.

JNJPositive Net Change XLVNegative Net Change IYHNegative Net Change IHENegative Net Change PPHNegative Net Change FTXHPositive Net Change

Zacks Equity Research

SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

RHHBYNegative Net Change SRPTNegative Net Change ARWRNegative Net Change

Kinjel Shah

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change VERVPositive Net Change

Zacks Equity Research

Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

NVSPositive Net Change RHHBYNegative Net Change JNJPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.

SNYNegative Net Change APLSNegative Net Change ARVNPositive Net Change AKRONegative Net Change

Zacks Equity Research

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.

JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change KVUEPositive Net Change

Mark Vickery

Strong Q2 Earnings, Cooling PPI Lead Pre-Markets Higher

Headline PPI for June, month over month, reached 0.0% -- lower than the +0.2% expected and 30 bps below May.

GSNo Net Change BACPositive Net Change MSPositive Net Change JNJPositive Net Change

Ahan Chakraborty

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change

Kinjel Shah

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

CPRXPositive Net Change TBPHPositive Net Change ALDXPositive Net Change LRMRPositive Net Change ZVRANegative Net Change

Ekta Bagri

Will Increased Expenses Affect Bristol Myers' Performance?

BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change

Sundeep Ganoria

How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

AZNNo Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change

Zacks Equity Research

BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?

Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.

REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change

Shaun Pruitt

3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS

The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.

ABTPositive Net Change NVSPositive Net Change JNJPositive Net Change

Zacks Equity Research

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

GSKNo Net Change MRKNegative Net Change GILDPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel performance.

GEPositive Net Change NFLXPositive Net Change LLYNegative Net Change WLFCPositive Net Change BDLNo Net Change